J. R. Mel

1.1k total citations
26 papers, 506 citations indexed

About

J. R. Mel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, J. R. Mel has authored 26 papers receiving a total of 506 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in J. R. Mel's work include Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). J. R. Mel is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Colorectal Cancer Treatments and Studies (7 papers) and Lung Cancer Research Studies (5 papers). J. R. Mel collaborates with scholars based in Spain, Poland and Mexico. J. R. Mel's co-authors include Miguel Martín, Lourdes Calvo, Encarna Adrover, Manuel Ramos, Montserrat Muñoz-Mateu, José Á. García-Sáenz, M.J. Escudero, Antonio Casado, Eva Carrasco and Àngels Arcusa and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

J. R. Mel

26 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. R. Mel Spain 11 429 143 136 47 47 26 506
Mariangela Ciccarese Italy 12 321 0.7× 155 1.1× 140 1.0× 26 0.6× 14 0.3× 31 479
Piotr Skotnicki Poland 12 135 0.3× 98 0.7× 97 0.7× 108 2.3× 69 1.5× 31 392
Franco Vito Piantedosi Italy 12 519 1.2× 124 0.9× 432 3.2× 34 0.7× 25 0.5× 14 698
T. Giannakakis Greece 13 367 0.9× 121 0.8× 90 0.7× 35 0.7× 56 1.2× 24 457
D. Dodwell United Kingdom 10 249 0.6× 63 0.4× 105 0.8× 28 0.6× 14 0.3× 14 393
M. Lallement France 7 282 0.7× 312 2.2× 179 1.3× 118 2.5× 15 0.3× 21 503
Ángel Martínez-Agulló Spain 9 412 1.0× 358 2.5× 130 1.0× 104 2.2× 10 0.2× 10 553
Anna Potamianou Greece 13 481 1.1× 198 1.4× 142 1.0× 20 0.4× 54 1.1× 37 716
Woo Kun Kim South Korea 13 376 0.9× 50 0.3× 242 1.8× 40 0.9× 57 1.2× 36 643
Nicholas J. Petrelli United States 8 325 0.8× 61 0.4× 88 0.6× 164 3.5× 12 0.3× 18 446

Countries citing papers authored by J. R. Mel

Since Specialization
Citations

This map shows the geographic impact of J. R. Mel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. R. Mel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. R. Mel more than expected).

Fields of papers citing papers by J. R. Mel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. R. Mel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. R. Mel. The network helps show where J. R. Mel may publish in the future.

Co-authorship network of co-authors of J. R. Mel

This figure shows the co-authorship network connecting the top 25 collaborators of J. R. Mel. A scholar is included among the top collaborators of J. R. Mel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. R. Mel. J. R. Mel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mesı́a, Ricard, José Á. García-Sáenz, Alicia Lozano, et al.. (2015). Phase II study with conventional radiotherapy (RT) + cetuximab in patients with advanced larynx cancer who responded to induction chemotherapy (IC): An organ preservation TTCC study.. Journal of Clinical Oncology. 33(15_suppl). 6037–6037. 2 indexed citations
3.
Salvador, J., Luís Manso, Juan de la Haba-Rodríguez, et al.. (2014). Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clinical & Translational Oncology. 17(2). 160–166. 10 indexed citations
4.
Grande, Carlos, Sonia Candamio, María José Villanueva, et al.. (2013). Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. Journal of Geriatric Oncology. 4(2). 114–121. 11 indexed citations
5.
Martín, Miguel, Pedro Sánchez‐Rovira, Montserrat Muñoz-Mateu, et al.. (2011). Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004–05 study. Annals of Oncology. 22(12). 2591–2596. 26 indexed citations
6.
Rubio, J. Casal, et al.. (2009). A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemotherapy and Pharmacology. 64(2). 379–384. 12 indexed citations
7.
8.
Vázquez‐Estévez, Sergio, Margarita Amenedo, Luis León‐Mateos, et al.. (2007). Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). Anti-Cancer Drugs. 18(10). 1201–1206. 2 indexed citations
9.
Casal, J., et al.. (2007). Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study. Cancer Chemotherapy and Pharmacology. 60(5). 725–732. 6 indexed citations
10.
11.
Tusquets, Ignasi, et al.. (2006). Preliminary results of docetaxel (T) and trastuzumab (H) combination administered every 21 days in metastatic breast cancer (MBC) and HER-2 over-expression patients (P). Journal of Clinical Oncology. 24(18_suppl). 10670–10670. 1 indexed citations
12.
Grande, Carlos, J. R. Mel, Mercedes Salgado, et al.. (2006). Multicenter phase II study of cetuximab and irinotecan as third line chemotherapy in patients (pts) with metastatic colorectal cancer (MCRC) previously treated with both irinotecan and oxaliplatin regimens. Journal of Clinical Oncology. 24(18_suppl). 13551–13551. 2 indexed citations
13.
Feliú, Jaime, Antonieta Salud, J. R. Mel, et al.. (2005). Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer. British Journal of Cancer. 93(11). 1230–1235. 31 indexed citations
14.
Espinosa, Enrique, Serafín Morales, Pablo Borrega, et al.. (2004). Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 54(6). 546–552. 14 indexed citations
15.
Vázquez‐Estévez, Sergio, Carlos Grande, Margarita Amenedo, et al.. (2004). Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006-00). Anti-Cancer Drugs. 15(5). 489–494. 12 indexed citations
16.
Chacón, José Ignacio, Joel Feliu i Samuel-Lajeunesse, José Á. García-Sáenz, et al.. (2004). Oxaliplatin (Ox) and raltitrexed (Ral) as first line treatment for locally advanced and metastatic gastric adenocarcinoma: Results of an ONCOPAZ phase II trial (OPHA 0141). Journal of Clinical Oncology. 22(14_suppl). 4213–4213. 2 indexed citations
17.
Viéitez, José María, M. González‐Barón, J. R. Mel, et al.. (2002). Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer. Lung Cancer. 39(1). 77–84. 3 indexed citations
18.
Vázquez‐Estévez, Sergio, et al.. (2002). Neo‐adjuvant treatment of infiltrating transitional‐cell carcinoma of the bladder with paclitaxel and cisplatin: A phase II trial. International Journal of Urology. 9(3). 162–166. 7 indexed citations
19.
Feliú, Jaime, J. R. Mel, Carlos Camps, et al.. (2002). Raltitrexed in the treatment of elderly patients with advanced colorectal cancer. European Journal of Cancer. 38(9). 1204–1211. 22 indexed citations
20.
Mel, J. R., et al.. (1986). Hereditary multiple glomus tumours.. Archives of Disease in Childhood. 61(8). 801–802. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mariangela Ciccarese Breakdown of academic impact, for papers by Piotr Skotnicki Breakdown of academic impact, for papers by Franco Vito Piantedosi Breakdown of academic impact, for papers by T. Giannakakis Breakdown of academic impact, for papers by D. Dodwell Breakdown of academic impact, for papers by M. Lallement Breakdown of academic impact, for papers by Ángel Martínez-Agulló Breakdown of academic impact, for papers by Anna Potamianou Breakdown of academic impact, for papers by Woo Kun Kim Breakdown of academic impact, for papers by Nicholas J. Petrelli
Rankless by CCL
2026